DTIL Precision BioSciences, Inc.
Healthcare$7.58+4.84%ClosedMarket Cap: $97.2M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
1.22
P/S
2.06
EV/EBITDA
-0.70
DCF Value
$-12.04
FCF Yield
-63.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
97.0%
Operating Margin
-86.8%
Net Margin
-98.7%
ROE
-81.2%
ROA
-30.9%
ROIC
-28.4%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $10.8M | 100.0% | $-9.1M | $-18.4M | $— | — |
| Q4 null | $34.2M | 98.0% | $12.5M | $19.2M | $— | — |
| FY null | $34.3M | 92.0% | $-52.1M | $-46.6M | $— | — |
| Q3 null | $13.0K | 100.0% | $-20.7M | $-21.8M | $— | — |
| Q2 null | $18.0K | -3766.7% | $-21.9M | $-23.5M | $— | — |
| Q1 null | $29.0K | 100.0% | $-22.1M | $-20.6M | $— | — |
| Q4 null | $638.0K | 100.0% | $-24.8M | $-17.7M | $— | — |
| FY null | $68.7M | 100.0% | $-26.2M | $7.2M | $— | — |
| Q3 null | $576.0K | 100.0% | $-21.3M | $-16.4M | $— | — |
| Q2 null | $49.9M | 100.0% | $24.1M | $32.7M | $— | — |
| Q1 null | $17.6M | 100.0% | $-4.2M | $8.6M | $— | — |
| Q4 2023 | $7.0M | 100.0% | $-14.9M | $-16.3M | $-3.66 | — |